Motowo Nakajima
25Patents
5h-index
46Co-inventors
69Inventor score
Filing activity: Feb 20, 1987 → Mar 9, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5262403A | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II | Physics | 31 | Expired |
| US4859581A | Endoglycosidase assay | Physics | 25 | Expired |
| US6277987A | Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives | Chemistry; Metallurgy | 22 | Expired |
| US5332812A | Solid-phase substrate containing modified heparin | Physics | 21 | Expired |
| US9012502B2 | Cancer heat therapy-enhancing agent | Human Necessities | 14 | Active |
| US9314443B2 | Enhancer of survival of transplanted organ | Human Necessities | 2 | Active |
| US9399029B2 | Immune tolerance inducer | Chemistry; Metallurgy | 2 | Active |
| US6410580B1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Chemistry; Metallurgy | 1 | Expired |
| US7138432B1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Chemistry; Metallurgy | 1 | Expired |
| US9089530B2 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient | Emerging Cross-Sectional Technologies | 1 | Active |
| US6461848B1 | Human heparanase polypeptide and cDNA | Human Necessities | 1 | Expired |
| US9962350B2 | Agent for improving normal development rate of fertilized eggs | Human Necessities | 0 | Active |
| US9474770B2 | Prophylactic agent and/or therapeutic agent for sepsis | Human Necessities | 0 | Active |
| US9539225B2 | Anemia of cancer improving/prophylactic agent | Human Necessities | 0 | Active |
| US9901558B2 | Enhancer of survival of transplanted organ | Human Necessities | 0 | Active |
| US9937138B2 | Enhancer of survival of transplanted organ | Human Necessities | 0 | Active |
| US9707196B2 | Treatment agent and/or prophylactic agent for side effects of cancer drugs | Human Necessities | 0 | Active |
| US9463175B2 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient | Emerging Cross-Sectional Technologies | 0 | Active |
| US9475755B2 | Prophylactic agent for chronic kidney disease | Chemistry; Metallurgy | 0 | Active |
| US8034810B2 | Arylsulfonamido-substituted hydroxamic acid derivatives | Chemistry; Metallurgy | 0 | Active |
| US9488664B2 | Diagnostic agent for tumor | Physics | 0 | Active |
| US9895331B2 | Prophylactic and/or therapeutic agent for radiation damage | Human Necessities | 0 | Active |
| US9469598B2 | Erythropoietin production-promoting agent | Human Necessities | 0 | Active |
| US10022345B2 | Agent for preventing and/or treating veisalgia | Human Necessities | 0 | Active |
| US9351949B2 | Prophylactic/therapeutic agent for influenza virus infection | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.